The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

Sign in to access this content
Sign InAnalysts at Seeking Alpha have reiterated a 'Strong Buy' rating for Harrow (HROW), setting a fair value target of $73.25, which implies an upside potential of over 100%. The analysis suggests that the recent sell-off in the stock is a market overreaction to short-term guidance disappointments. Long-term growth is expected to be driven by the company's core assets, Vevye and Iheezo, which remain fundamentally strong. The financial model projects a robust EBIT margin of 32–45% for the period between 2029 and 2035. These projections underscore analyst confidence in Harrow's long-term trajectory despite current market volatility. Consequently, the current valuation gap is viewed as a significant buying opportunity for investors looking for growth in the pharmaceutical sector.